FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology and can be used in medicine. Invention discloses an anti-claudin antibody conjugate with at least one exatecan fragment (see compound of general formula (Pc-L-Y-D)), where Pc is an antibody to claudin 18.2 or its antigen-binding fragment, and L, Y and n are as defined in the present description.
EFFECT: invention can be used in preparing a drug for treating cancer, the cells of which are characterized by high expression of claudin 18.2.
31 cl, 16 ex, 17 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
